Stereotactic body radiation extends survival in hepatocellular carcinoma

Stereotactic body radiation therapy followed by sorafenib extended survival compared with sorafenib alone among patients with hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.Patients treated with stereotactic body radiation therapy (SBRT) achieved longer PFS and OS with no increase in adverse events, results of the NRG Oncology/RTOG 1112 study showed.Researchers also reported “a strong suggestion” of quality-of-life benefit at 6 months in the SBRT group.“The take-home message is that radiation is an effective therapyRead More